Search

Your search keyword '"Piette, Jean"' showing total 1,376 results
Start Over Author "Piette, Jean"
1,376 results on '"Piette, Jean"'

218. Rituximab-associated Vasculitis Flare: Incidence, Predictors, and Outcome

Author

Desbois, Anne Claire, primary, Biard, Lucie, additional, Sène, Damien, additional, Brocheriou, Isabelle, additional, Rouvier, Philippe, additional, Lioger, Bertrand, additional, Musset, Lucile, additional, Candon, Sophie, additional, Zenone, Thierry, additional, Resche-Rigon, Matthieu, additional, Piette, Jean-Charles, additional, Benameur, Neila, additional, Cacoub, Patrice, additional, and Saadoun, David, additional

Published
2019
Full Text
View/download PDF

240. Susac syndrome

Author

Papo, Thomas, Biousse, Valerie, Lehoang, Phuc, Fardeau, Christine, N'Guyen, Nicolas, Huong, Du Le Thi, Aumaitre, Olivier, Bousser, Marie-Germaine, Godeau, Pierre, and Piette, Jean-Charles

Subjects
Arterial occlusions -- Diagnosis, Retinal diseases -- Care and treatment
Published
1998

243. Systemic capillary leak syndrome: report on 13 patients with special focus on course and treatment

Author

Amoura, Zahir, Papo, Thomas, Ninet, Jacques, Hatron, Pierre-Yves, Guillaumie, Jacques, Piette, Anne-Marie, Bletry, Olivier, Dequiedt, Philippe, Talasczka, Aline, Rondeau, Eric, Dutel, Jean Louis, Wechsler, Bertrand, and Piette, Jean-Charles

Subjects
Capillaries -- Diseases, Health, Health care industry
Abstract

BACKGROUND: Systemic capillary leak syndrome (SCLS) is a rare condition characterized by unexplained episodic capillary hyperpermeability due to a shift of fluid and protein from the intravascular to the interstitial space. This results in diffuse swelling, weight gain, and renal shut-down. From the first publication in 1960, only 34 cases have been reported. OBJECTIVE: To collate enough patients to observe the natural history of the disease and evaluate the efficacy of empiric treatments. DESIGN: Multicentric retrospective study. RESULTS: Thirteen patients (6 women and 7 men) were collated with a mean follow-up of 6.4 years. Eight patients are still alive after a mean of 5.6 years (range 1 to 15). Three patients out of the 11 who were not lost to follow-up died; 1 during an attack and 2 because of a progression towards multiple myeloma. CONCLUSIONS: Our series shows an improvement in the prognosis of SCLS due most likely to improved management during attacks. Some patients' disease could evolve into a multiple myeloma. Treatment is still empiric and no prophylactic therapy, including terbutaline associated with aminophylline, has clearly proven its efficacy.

Published
1997

244. Endomyocardial fibrosis in Behcet's disease

Author

Huong, Du Le Thi, Wechsler, Bertrand, Papo, Thomas, De Zuttere, Dominique, Bletry, Olivier, Hernigou, Anne, Delcourt, Annick, Godeau, Pierre, and Piette, Jean-Charles

Subjects
Behcet's disease -- Complications, Fibrosis -- Physiological aspects, Heart muscle -- Abnormalities, Health
Abstract

Behcet's disease may be one cause of a heart disease called endomyocardial fibrosis. Details of the imaging tests performed to identify endomyocardial fibrosis in four patients with Behcet's disease are presented. Tissue sample tests revealed the heart condition in three of these patients. The condition was discovered during surgery in the fourth patient. Contrast imaging tests indicated an abnormally small heart chamber size. A mass was visible on two cross-sectional imaging tests. Ultrasound tests showed a bright image in the area of the heart lining tissue.

Published
1997

245. Antiendothelial cell antibodies: useful markers of systemic sclerosis

Author

Salojin, Konstantin V., Le Tonqueze, Michelle, Saraux, Alain, Nassonov, Evgeni L., Dueymes, Maryvonne, Piette, Jean-Charles, and Youinou, Pierre Y.

Subjects
Systemic scleroderma -- Diagnosis, Endothelium -- Physiological aspects, Anti-antibodies -- Analysis, Health, Health care industry
Abstract

BACKGROUND: Systemic sclerosis (SS) encompasses a wide spectrum of clinical presentations. Antiendothelial cell antibodies (AECA) in patients with primary Raynaud's phenomenon (PRP), limited SS (ISSc), or diffuse SS (dSSc) may help to determine the long-term prognosis of the disease. METHODS: Twenty-seven normal controls, 13 patients with PRP, 36 with ISSc, and 31 with dSSc were included in the study. Sera were examined for the presence of AECA, using a cellular enzyme-linked immunosorbent assay (ELISA). Angiotensin-converting enzyme (ACE) activity, plasma von Willebrand factor antigen (vWfAg), and thrombomodulin (Tm) concentrations were also evaluated. The medical records of 50 of the ISSc and dSSc patients were reviewed and the organ system involvement noted. RESULTS: Antiendothelial cell antibodies were present in 3 patients with PRP, 16 patients with ISSc, and 26 patients with dSSc. These autoantibodies were mainly of the IgG isotype. There was no difference in ACE activity between patients and controls. In contrast, vWfAg and Tm concentrations were higher in patients with PRP relative to controls, and higher in patients with ISSc compared with those with PRP. The presence of AECA was associated with digital scars and ulcers (P [is less than] 0.004 and P [is less than] 0.003, respectively), severe RP (P [is less than] 0.01), grade 3 tortuosity of vessels (P [is less than] 0.0004), and lung involvement (P [is less than] 0.02). CONCLUSION: The significant trend for AECA to increase with disease severity across the three groups of patients studied suggests that the AECA test can identify subsets of SSc with differing prognoses.

Published
1997

Catalog

Books, media, physical & digital resources
See catalog results